{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:44:04Z","timestamp":1786373044127,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Elevated circulating fibroblast growth factor 23 (FGF23) predicts progression of CKD, but it is unknown whether circulating FGF23 independently predicts incident CKD. This study aimed to determine whether circulating FGF23 predicts incident CKD in community-dwelling women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      This study examined the relationship of intact serum FGF23, 1,25-dihydroxyvitamin D\n                      <jats:sub>3<\/jats:sub>\n                      (1,25[OH]\n                      <jats:sub>2<\/jats:sub>\n                      D), 25-hydroxyvitamin D (25[OH]D), parathyroid hormone, calcium, and phosphate with prevalent and incident CKD in 701 disabled women, \u226565 years of age, from the Women\u2019s Health and Aging Study I in Baltimore, Maryland, from 1993 to 1997. Incident CKD was defined as a low estimated GFR (eGFR) &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      only, low eGFR &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and a \u226525% decline in eGFR from baseline, and an increase in serum creatinine (\u22650.4 mg\/dl) at follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, 381 women (54.3%) had stage 3 CKD. Of 307 women without CKD at baseline, 63 (20.5%) developed stage 3 CKD over 24 months of follow-up. After excluding prevalent cases of CKD, FGF23 (per 1 SD increase) was associated with incident stage 3 CKD (hazard ratio [HR], 1.51; 95% confidence interval [95% CI], 1.06, 2.16;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02), low and declining eGFR (HR, 3.69; 95% CI, 1.68, 8.11;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001), and increase in serum creatinine (HR, 5.35; 95% CI, 1.27, 22.54;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02) in respective multivariable Cox proportional hazards models adjusting for baseline eGFR, age, race, phosphate, 1,25-dihydroxyvitamin D\n                      <jats:sub>3<\/jats:sub>\n                      , parathyroid hormone, and other potential confounders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated FGF23 is an independent risk factor for incident CKD in older, disabled, community-dwelling women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.08070811","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:41:39Z","timestamp":1320972099000},"page":"85-91","source":"Crossref","is-referenced-by-count":32,"title":["Serum Fibroblast Growth Factor-23 and Risk of Incident Chronic Kidney Disease in Older Community-Dwelling Women"],"prefix":"10.2215","volume":"7","author":[{"given":"Richard D.","family":"Semba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Cappola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Crasto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda P.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20230811","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States.","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"R2-15-20230811","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: Effects on the cardiovascular system.","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"key":"R3-15-20230811","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.291.7.844","article-title":"Predictors of new-onset kidney disease in a community-based population.","volume":"291","author":"Fox","year":"2004","journal-title":"JAMA"},{"key":"R4-15-20230811","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.semnephrol.2009.07.002","article-title":"Chronic inflammation potentiates kidney aging.","volume":"29","author":"Mei","year":"2009","journal-title":"Semin Nephrol"},{"key":"R5-15-20230811","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/en.2010-0800","article-title":"Minireview: Fibroblast growth factor 23 in phosphate homeostasis and bone metabolism.","volume":"152","author":"Hori","year":"2011","journal-title":"Endocrinology"},{"key":"R6-15-20230811","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.tem.2009.02.001","article-title":"Bone as an endocrine organ.","volume":"20","author":"Fukumoto","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"R7-15-20230811","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"R8-15-20230811","first-page":"4003","article-title":"The parathyroid is a target organ for FGF23 in rats.","volume":"117","author":"Ben-Dov","year":"2007","journal-title":"J Clin Invest"},{"key":"R9-15-20230811","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study.","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R10-15-20230811","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1681\/ASN.2010080894","article-title":"Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.","volume":"22","author":"Wolf","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R11-15-20230811","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"R12-15-20230811","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","article-title":"Forging forward with 10 burning questions on FGF23 in kidney disease.","volume":"21","author":"Wolf","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R14-15-20230811","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"R16-15-20230811","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/aje\/kwp151","article-title":"Defining incident chronic kidney disease in the research setting: The ARIC Study.","volume":"170","author":"Bash","year":"2009","journal-title":"Am J Epidemiol"},{"key":"R17-15-20230811","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R18-15-20230811","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R19-15-20230811","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1210\/jcem-33-6-992","article-title":"Competitive protein-binding radioassay for 25-hydroxycholecalciferol.","volume":"33","author":"Haddad","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-15-20230811","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jcem-58-1-91","article-title":"A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies.","volume":"58","author":"Reinhardt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-15-20230811","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/clinchem\/33.8.1364","article-title":"Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia.","volume":"33","author":"Nussbaum","year":"1987","journal-title":"Clin Chem"},{"key":"R22-15-20230811","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia.","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-15-20230811","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure.","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"key":"R25-15-20230811","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"R28-15-20230811","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(81)90791-1","article-title":"The horse-racing effect.","volume":"2","author":"Peto","year":"1981","journal-title":"Lancet"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201201000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:30Z","timestamp":1786369290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201201000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.08070811","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}